Table 1.

Subject demographics and neuropathologic assessment

Case	Age in years	Gender	Break stage	CERAD plaque score	Level of AD pathologic change	CAA
AD with CAA type 1
1	79	M	VI	3	High	Severe
2	78	F	VI	2	High	Severe
3	68	F	VI	3	High	Severe
4	101	M	V	2	High	Severe
5	73	M	V	2	High	Severe
6	75	M	VI	3	High	Severe
7	76	M	VI	1	Intermediate	Moderate
8	80	M	VI	3	High	Severe
AD with CAA type 2
1	76	M	VI	3	High	Severe
2	93	F	VI	3	High	Moderate
3	69	F	VI	3	High	Severe
4	86	F	IV-V	3	Intermediate-high Moderate
5	82	F	VI	3	High	Severe
6	78	M	VI	2	High	Severe
7	68	M	VI	2	High	Severe
8	64	F	VI	1	Intermediate	Severe
9	96	F	VI	2	High	Moderate
10	70	M	VI	2	High	Moderate
AD without CAA
1	65	F	VI	2–3	High	No CAA
2	115	F	IV-V	2	Intermediate-high No CAA
3	81	F	V	3	High	No CAA
4	63		VI, also DLBD	3	High	No CAA
5	61	M	VI	3	High	No CAA
6	70	M	VI	3	High	No CAA
7	93	M	V-VI	1–2	Intermediate-high	No CAA
Nondemented elderly
1	71	M	II	0	Low	No CAA
2	76	F	<IV	0	Not	No CAA
3	66	M	I	0	Low	No CAA
4	79	F	II	0	Not	No CAA
5	64	F	<IV	0	Not	No CAA
6	67	M	I	0	Not	No CAA
7	75	F	III-IV	0	Low	No CAA
8	65	M	I-II	0	Not	No CAA
9	75	M	I	0	Not	No CAA
10	89	M	<IV	0	Low	No CAA

Key: AD, Alzheimer disease; CERAD, Consortium to Establish a Registry for AD; CAA, cerebral amyloid angiopathy; DLBD, diffuse Lewy body disease.